InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
5
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-15.8%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by He Wei-Wu, Chairman & CEO. Officer active across 1 company, notably CASI Pharmaceuticals, Inc.. Cumulatively, 5 filings have been published. Breakdown: 5 buys · 0 sell. Total volume traded: €1.1m. History available since 18 August 2021. The latest transaction was disclosed on 13 June 2022 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations5 total
36,058 shares@ US$2.973.55% mcap9.2% of flowCommon StockSEC:0001104659-22-072392:0
Ideal exit: 10 Mar 2023 (T+270)
200,000 shares@ US$0.996.04% mcap15.7% of flowCommon StockSEC:0001104659-21-141867:0
Ideal exit: 14 Aug 2022 (T+270)
200,000 shares@ US$0.9915.7% of flowCommon StockSEC:0001104659-21-141867
Ideal exit: 14 Aug 2022 (T+270)
300,000 shares@ US$1.2911.41% mcap29.7% of flowCommon StockSEC:0001104659-21-108182:0
Ideal exit: 15 May 2022 (T+270)
300,000 shares@ US$1.2929.7% of flowCommon StockSEC:0001104659-21-108182
Ideal exit: 15 May 2022 (T+270)
5 of 5 declarations
About He Wei-Wu
He Wei-Wu is the Chairman and CEO of CASI Pharmaceuticals, Inc., a company focused on developing innovative treatments for serious diseases. Under his leadership, the company is committed to providing high-quality therapeutic solutions and improving patients' lives. He Wei-Wu plays a key role in the company's strategy and vision, overseeing operations and guiding the team towards achieving growth and innovation objectives.
